Copy to clipboard 
Precipart, a contract manufacturer of precision components for the medical device industry, will receive investment support from KKR via organic growth and M&A.
Founded in 1950 by the Laubscher family, Precipart manufactures highly engineered custom components, offering services such as design, engineering, manufacturing and assembly for OEMs across a range of end market segments, including surgical robotics.
Oliver Laubscher, CEO of Precipart, commented: “My family and I are thrilled to form this strategic partnership with KKR. With KKR’s differentiated industry insights, global network, and deep bench of resources, we will be able to expand our capability offerings substantially, serve our customers better and at greater scale, and make Precipart an even better home for our talented employees. We look forward to working with the KKR team to build on what we have accomplished over the past 73 years.”
Ali Satvat, Partner and Global Head of Health Care Strategic Growth at KKR, said: “We believe that Precipart has the foundational strength and customer orientation to become a global platform and are thrilled to collaborate with the Company on its growth ambitions. This investment is a solid example of our Health Care Strategic Growth approach of backing leaders in thematic areas that we have followed over time and for which we believe that KKR can serve as a strategic partner in helping reach scale.”
KKR is investing in Precipart through its Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth healthcare-related companies.
Source: Precipart
